TCG Crossover Management, LLC
- SEC CIK
- 0001839948
- Latest filing
- Aug 14, 2026
Holdings in Q2 2024
Holdings as of Jun 30, 2024, filed Aug 14, 2024. Long positions only; changes compare share counts with Q1 2024.
- Positions
- 32
- −1 vs. Q1 2024
- Portfolio value
- $959.5M
- −$305.4M (−24.1%) vs. Q1 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| CGONCG Oncology, Inc. | COM | 3,670,206 | $115.9M | 12.1% | +100,000+2.8% | Added | History |
| DYNDyne Therapeutics, Inc. | COM | 2,650,150 | $93.5M | 9.7% | 00.0% | Unchanged | History |
| ABVXAbivax S.A. | SPONSORED ADS | 6,056,596 | $80.1M | 8.3% | +4,956,596+450.6% | Added | History |
| SLNSilence Therapeutics plc | ADS | 3,295,350 | $62.6M | 6.5% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 6,964,375 | $58.7M | 6.1% | +750,000+12.1% | Added | History |
| SVRASavara Inc | COM | 12,362,205 | $49.8M | 5.2% | +2,362,205+23.6% | Added | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 149,283 | $41.8M | 4.4% | 00.0% | Unchanged | History |
| EWTXEdgewise Therapeutics, Inc. | COM | 2,272,728 | $40.9M | 4.3% | 00.0% | Unchanged | History |
| KROSKeros Therapeutics, Inc. | COM | 879,344 | $40.2M | 4.2% | 00.0% | Unchanged | History |
| MLYSMineralys Therapeutics, Inc. | COM | 3,185,185 | $37.3M | 3.9% | 00.0% | Unchanged | History |
| OCULOcular Therapeutix, Inc | COM | 5,319,148 | $36.4M | 3.8% | 00.0% | Unchanged | History |
| TYRATyra Biosciences, Inc. | COM | 1,989,103 | $31.8M | 3.3% | 00.0% | Unchanged | History |
| KURAKura Oncology, Inc. | COM | 1,423,642 | $29.3M | 3.1% | 00.0% | Unchanged | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 694,547 | $27.3M | 2.8% | −903,874−56.5% | Reduced | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 2,890,816 | $26.1M | 2.7% | +850,000+41.7% | Added | History |
| ATXSAstria Therapeutics, Inc. | COM | 2,761,861 | $25.1M | 2.6% | −2,517,067−47.7% | Reduced | History |
| CMPSCOMPASS Pathways plc | SPONSORED ADS | 3,858,000 | $23.3M | 2.4% | 00.0% | Unchanged | History |
| SLNOSoleno Therapeutics Inc | COM NEW | 550,000 | $22.4M | 2.3% | 00.0% | Unchanged | History |
| IRONDisc Medicine, Inc. | COM | 486,957 | $21.9M | 2.3% | +486,957 | New | History |
| TRMLTourmaline Bio, Inc. | COM | 1,477,593 | $19.0M | 2.0% | 00.0% | Unchanged | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 556,317 | $15.1M | 1.6% | −237,512−29.9% | Reduced | History |
| ADVMAdverum Biotechnologies, Inc. | COM | 2,008,340 | $13.8M | 1.4% | 00.0% | Unchanged | History |
| VTGNVistagen Therapeutics, Inc. | COM NEW | 2,676,580 | $9.31M | 1.0% | 00.0% | Unchanged | History |
| TRDAEntrada Therapeutics, Inc. | COM | 584,955 | $8.34M | 0.9% | 00.0% | Unchanged | History |
| EYPTEyePoint, Inc. | COM NEW | 922,335 | $8.02M | 0.8% | +922,335 | New | History |
| CCCCC4 Therapeutics, Inc. | COM STK | 1,276,574 | $5.90M | 0.6% | 00.0% | Unchanged | History |
| NKTRNektar Therapeutics | COM | 4,000,000 | $4.96M | 0.5% | 00.0% | Unchanged | History |
| JBIOJade Biosciences, Inc. | COM | 2,240,809 | $3.72M | 0.4% | +39,535+1.8% | Added | History |
| ANTXAN2 Therapeutics, Inc. | COM | 1,555,118 | $3.34M | 0.3% | 00.0% | Unchanged | History |
| KODKodiak Sciences Inc. | COM | 899,999 | $2.11M | 0.2% | 00.0% | Unchanged | History |
| VTYXVentyx Biosciences, Inc. | COM | 316,195 | $730.4K | 0.1% | −499,529−61.2% | Reduced | History |
| CABACabaletta Bio, Inc. | COM | 86,795 | $649.2K | 0.1% | 00.0% | Unchanged | History |
Sold out since Q1 2024 (3)
Positions held at the end of Q1 2024 that are gone from this filing.
| Security | Class | Shares in Q1 2024 | Value in Q1 2024 | % of portfolio in Q1 2024 | History |
|---|---|---|---|---|---|
| INBXInhibrx Biosciences, Inc. | COM | 1,750,387 | $61.2M | 4.8% | History |
| GERNGeron Corp | COM | 17,391,639 | $57.4M | 4.5% | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 1,163,356 | $13.8M | 1.1% | History |